REC-4881
Familial adenomatous polyposis
REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP, a rare tumor predisposition syndrome. There are currently no FDA-approved therapies for the treatment of FAP. MEK1/2 inhibition to target FAP was identified using phenotypic insights by the Recursion OS.
Learn more on clinicaltrials.gov.
*Prevalence for adult and pediatric population. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
